Marshall R J, McGrath J C, Miller R D, Docherty J R, Lamar J C
Br J Anaesth. 1980;52 Suppl 1:21S-32S. doi: 10.1093/bja/52.suppl_1.21s.
The cardiovascular actions of 1- [(2 beta,3 alpha, 16 beta,17 beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methyl-piperidinium bromide (Org NC 45) are reviewed and compared with those of other non-depolarizing neuromuscular blocking drugs. Results obtained in anaesthetized cats and dogs have demonstrated that, in contrast to other neuromuscular blocking drugs, Org NC 45, even in doses 20 times greater than those required for neuromuscular block, has no effects on heart rate, arterial pressure, autonomic ganglia, adrenoceptors or baroreceptors activity. Studies in pithed rats and on guineapig atria have further shown that Org NC 45 has little effect on cardiac muscarinic receptors or on noradrenaline re-uptake mechanisms. These results suggest that Org NC 45 possesses significant advantages over presently used non-depolarizing neuromuscular blocking drugs, since its clinical use should not be associated with cardiovascular side-effects.
本文综述了1-[(2β,3α,16β,17β)-3,17-双(乙酰氧基)-2-(1-哌啶基)-雄甾烷-16-基]-1-甲基哌啶溴化物（Org NC 45）的心血管作用，并与其他非去极化型神经肌肉阻滞药物进行了比较。在麻醉猫和狗身上获得的结果表明，与其他神经肌肉阻滞药物不同，即使Org NC 45的剂量比神经肌肉阻滞所需剂量大20倍，它对心率、动脉血压、自主神经节、肾上腺素能受体或压力感受器活性也没有影响。在脊髓横断大鼠和豚鼠心房上进行的研究进一步表明，Org NC 45对心脏毒蕈碱受体或去甲肾上腺素再摄取机制几乎没有影响。这些结果表明，Org NC 45相对于目前使用的非去极化型神经肌肉阻滞药物具有显著优势，因为其临床应用不应伴有心血管副作用。
